Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chessari

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Journal of Medicinal Chemistry|January 1, 2008
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activatorMartyn Frederickson, Owen Callaghan, Gianni Chessari, et al.
Journal of Medicinal Chemistry|February 17, 2006
Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitorsNigel Howard, Chris Abell, Wendy Blakemore, et al.
Cell Death & Disease|July 23, 2013
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesotheliomaN Crawford, I Stasik, C Holohan, et al.
Journal of Medicinal Chemistry|September 14, 2022
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent InhibitorJeffrey D St Denis, Gianni Chessari, Anne Cleasby, et al.
Journal of Medicinal Chemistry|February 24, 2007
Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretaseMiles Congreve, David Aharony, Jeffrey Albert, et al.
Journal of Medicinal Chemistry|October 3, 2003
Trisubstituted acridine derivatives as potent and selective telomerase inhibitorsR John Harrison, Javier Cuesta, Gianni Chessari, et al.
Nature Chemical Biology|October 2, 2012
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein functionSusanne M Saalau-Bethell, Andrew J Woodhead, Gianni Chessari, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Journal of Medicinal Chemistry|August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiencyChristopher W Murray, Maria G Carr, Owen Callaghan, et al.
Oncotarget|January 23, 2016
PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapyChris W D Armstrong, Pamela J Maxwell, Chee Wee Ong, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Journal of Medicinal Chemistry|January 1, 2008
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activatorMartyn Frederickson, Owen Callaghan, Gianni Chessari, et al.
Journal of Medicinal Chemistry|February 17, 2006
Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitorsNigel Howard, Chris Abell, Wendy Blakemore, et al.
Cell Death & Disease|July 23, 2013
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesotheliomaN Crawford, I Stasik, C Holohan, et al.
Journal of Medicinal Chemistry|September 14, 2022
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent InhibitorJeffrey D St Denis, Gianni Chessari, Anne Cleasby, et al.
Journal of Medicinal Chemistry|February 24, 2007
Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretaseMiles Congreve, David Aharony, Jeffrey Albert, et al.
Journal of Medicinal Chemistry|October 3, 2003
Trisubstituted acridine derivatives as potent and selective telomerase inhibitorsR John Harrison, Javier Cuesta, Gianni Chessari, et al.
Nature Chemical Biology|October 2, 2012
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein functionSusanne M Saalau-Bethell, Andrew J Woodhead, Gianni Chessari, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Journal of Medicinal Chemistry|August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiencyChristopher W Murray, Maria G Carr, Owen Callaghan, et al.
Oncotarget|January 23, 2016
PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapyChris W D Armstrong, Pamela J Maxwell, Chee Wee Ong, et al.
Pageof 8